IceCure Medical Ltd. (NASDAQ:ICCM) Given Consensus Rating of “Hold” by Analysts

IceCure Medical Ltd. (NASDAQ:ICCM) has been assigned an average rating of “Hold” from the four brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $2.6350.

A number of analysts recently commented on the stock. Wall Street Zen upgraded shares of IceCure Medical from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research note on Tuesday, April 21st. Finally, Alliance Global Partners assumed coverage on shares of IceCure Medical in a research note on Monday. They issued a “buy” rating for the company.

Institutional Trading of IceCure Medical

Institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in IceCure Medical in the 4th quarter worth approximately $67,000. Virtu Financial LLC acquired a new stake in IceCure Medical during the 4th quarter valued at approximately $39,000. Finally, Concurrent Investment Advisors LLC acquired a new stake in IceCure Medical during the 4th quarter valued at approximately $48,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

IceCure Medical Trading Up 0.9%

Shares of NASDAQ:ICCM traded up $0.00 during trading on Monday, reaching $0.30. The stock had a trading volume of 25,973 shares, compared to its average volume of 438,586. IceCure Medical has a one year low of $0.25 and a one year high of $1.40. The company has a market capitalization of $24.68 million, a P/E ratio of -1.27 and a beta of 0.47. The firm’s 50-day simple moving average is $0.47 and its 200 day simple moving average is $0.60.

IceCure Medical (NASDAQ:ICCM) last released its earnings results on Sunday, February 15th. The company reported $0.06 EPS for the quarter. The company had revenue of $1.28 million during the quarter. IceCure Medical had a negative net margin of 445.61% and a negative return on equity of 221.04%. Equities research analysts forecast that IceCure Medical will post -0.12 earnings per share for the current fiscal year.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.